Literature DB >> 10852446

Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance.

M Stowasser1, A W Bachmann, P R Huggard, T R Rossetti, R D Gordon.   

Abstract

In familial hyperaldosteronism type I (FH-I), inheritance of a hybrid 11beta-hydroxylase/aldosterone synthase gene causes ACTH-regulated aldosterone overproduction. In an attempt to understand the marked variability in hypertension severity in FH-I, we compared clinical and biochemical characteristics of 9 affected individuals with mild hypertension (normotensive or onset of hypertension after 15 yr, blood pressure never >160/100 mm Hg, < or = 1 medication required to control hypertension, no history of stroke, age >18 yr when studied) with those of 17 subjects with severe hypertension (onset before 15 yr, or systolic blood pressure >180 mm Hg or diastolic blood pressure >120 mm Hg at least once, or > or = 2 medications, or history of stroke). Severe hypertension was more frequent in males (11 of 13 males vs. 6 of 13 females; P < 0.05). All 4 subjects still normotensive after age 18 yr were females. Of 10 other affected, deceased individuals (7 males and 3 females) from a single family, all six who died before 60 yr of age (4 by stroke) were males. Biochemical studies were conducted in 6 mild and 16 severe subjects. The 2 groups were similar in terms of urinary sodium excretion. Mild subjects tended, although not significantly, to have lower urinary 18-oxo-cortisol (mean +/- SD, 27.4 +/- 9.0 vs. 35.2 +/- 12.9 nmol/mmol creatinine x day), higher plasma potassium (4.0 +/- 0.3 vs. 3.6 +/- 0.4 mmol/L), and lower recumbent (0800 h after overnight recumbency) plasma aldosterone levels (498 +/- 279 vs. 744 +/- 290 pmol/L). Upright (midmorning after 2-3 h of upright posture) plasma aldosterone levels were similar (mild, 485 +/- 150; severe, 474 +/- 188 pmol/L). In 1 normotensive female, upright PRA was much higher, and the upright aldosterone/PRA ratio was much lower than that in the other subjects. The remaining mild subjects had similar upright PRA levels (mild, 2.8 +/- 1.4; severe, 3.7 +/- 3.2 pmol/ L x min) and aldosterone/PRA ratios (mild, 199.5 +/- 133.4; severe, 200.6 +/- 150.9) as severe subjects. During angiotensin II (AII) infusion studies (n = 6 mild and 10 severe), performed during recumbency, aldosterone levels were lower in the mild group both basally (404 +/- 144 vs. 843 +/- 498 pmol/L; P < 0.05) and after 60 min AII (2 ng/kg x min; 261 +/- 130 vs. 520 +/- 330 pmol/L; P < 0.05). Aldosterone was unresponsive (rose by <50%) to AII in all subjects. Day curve studies (blood collected every 2 h for 24 h; n = 2 mild and 7 severe) demonstrated abnormal regulation of aldosterone by ACTH rather than by AII in both groups. In conclusion, in this series of patients with FH-I, males had more severe hypertension, and the degree of hybrid gene-induced aldosterone overproduction may have contributed to the severity of hypertension.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852446     DOI: 10.1210/jcem.85.6.6651

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

2.  Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration.

Authors:  Hyung-Suk Kim; Gene Lee; Simon W M John; Nobuyo Maeda; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 3.  Pathogenesis of Primary Aldosteronism: Impact on Clinical Outcome.

Authors:  Lucas S Santana; Augusto G Guimaraes; Madson Q Almeida
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

Review 4.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

5.  Genetic analyses of the chimeric CYP11B1/CYP11B2 gene in a Korean family with glucocorticoid-remediable aldosteronism.

Authors:  Ihn Suk Lee; Seul Young Kim; Hye Won Jang; Min Kyeong Kim; Ju Hee Lee; Yun Hyeong Lee; Young Suk Jo
Journal:  J Korean Med Sci       Date:  2010-08-14       Impact factor: 2.153

6.  Sex differences and central protective effect of 17beta-estradiol in the development of aldosterone/NaCl-induced hypertension.

Authors:  Baojian Xue; Daniel Badaue-Passos; Fang Guo; Celso E Gomez-Sanchez; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-06       Impact factor: 4.733

Review 7.  Aldosterone and the risk of hypertension.

Authors:  Vanessa Xanthakis; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

8.  Prevalence and characterization of somatic mutations in Chinese aldosterone-producing adenoma patients.

Authors:  Baojun Wang; Xintao Li; Xu Zhang; Xin Ma; Luyao Chen; Yu Zhang; Xiangjun Lyu; Yuzhe Tang; Qingbo Huang; Yu Gao; Yang Fan; Jinzhi Ouyang
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

9.  The Genotype-Based Morphology of Aldosterone-Producing Adrenocortical Disorders and Their Association with Aging.

Authors:  Xin Gao; Yuto Yamazaki; Yuta Tezuka; Kei Omata; Yoshikiyo Ono; Ryo Morimoto; Yasuhiro Nakamura; Fumitoshi Satoh; Hironobu Sasano
Journal:  Endocrinol Metab (Seoul)       Date:  2021-02-24

10.  Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.

Authors:  Chung-Yi Cheng; Hung-Wei Liao; Kang-Yung Peng; Tso-Hsiao Chen; Yen-Hung Lin; Jeff S Chueh; Vin-Cent Wu
Journal:  Biomedicines       Date:  2021-12-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.